209960-85-0

Upstream product

• 157665-51-5 3-fluoro-4-nitrobenzoyl chloride 
• 123-75-1 pyrrolidine 
• 455-87-8 4-amino-3-fluorobenzoic acid 
• 403-21-4 3-fluoro-4-nitrobenzoic acid 
• 552832-89-0 (3-fluoro-4-nitro-phenyl)-pyrrolidin-1-yl-methanone 
• 446-34-4 2-fluoro-4-methyl-1-nitrobenzene 

Downstream Products

• 855869-58-8 2-(3-cyano-4-fluoro-phenyl)-5-trifluoromethyl-2H-pyrazole-3-carboxylic acid [2-fluoro-4-(pyrrolidine-1-carbonyl)-phenyl]-amide 
• 218299-60-6 1-(3'-aminobenzisoxazol-5'-yl)-3-ethyl-5-[[2-fluoro-4-(N-pyrrolidinocarbonyl)phenyl]aminocarbonyl]pyrazole TFA salt 
• 218299-71-9 1-(3'-aminobenzisoxazol-5'-yl)-5-[(2-fluoro-4-(N-pyrrolidinocarbonyl)phenyl)aminocarbonyl]tetrazole trifluoroacetic acid salt 
• 218298-94-3 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[2-fluoro-4-(N-pyrrolidinocarbonyl)phenyl-aminocarbonyl]pyrazole 
• 552832-90-3 1-(4-chloro-3-nitro-phenyl)-1H-tetrazole-5-carboxylic acid [2-fluoro-4-(pyrrolidine-1-carbonyl)-phenyl]-amide 

Relevant academic research and scientific papers

NOVEL PYRROLOY2,3-d¨PYRIMIDINE COMPOUND

Disclosed is a novel pyrrolo[2,3-d]pyrimidine compound represented by formula [I] or a pharmacologically acceptable salt thereof, which has a GPR119 receptor agonistic activity and is useful for a pharmaceutical. In formula [I], E represents a group repre

SUBSTITUTED THIOPHEN-CARBOXYLIC ACID AMIDES, THE PRODUCTION AND THE USE THEREOF IN THE FORM OF A DRUG

The invention relates to novel substituted thiophen-2-carboxylic acid amides of general formula (I), wherein A and R1 to R8 are defined as specified in the claim 1, the tautomers, enantiomers, diastereomers, mixtures and salts thereof, in particular the salts thereof which are physiologically compatible with inorganic or organic acids or bases and exhibit interesting properties.

Discovery of 1-(3′-aminobenzisoxazol-5′-yl)-3-trifluoromethyl- N-[2-fluoro-4-[(2′-dimethylaminomethyl)imidazol-1-yl]phenyl] -1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor

Modification of a series of pyrazole factor Xa inhibitors to incorporate an aminobenzisoxazole as the P1 ligand resulted in compounds with improved selectivity for factor Xa relative to trypsin and plasma kallikrein. Further optimization of the P4 moiety led to compounds with enhanced permeability and reduced protein binding. The SAR and pharmacokinetic profile of this series of compounds is described herein. These efforts culminated in 1-(3′-aminobenzisoxazol-5′-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2′-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide (11d), a potent, selective, and orally bioavailable inhibitor of factor Xa. On the basis of its excellent in vitro potency and selectivity profile, high free fraction in human plasma, good oral bioavailability, and in vivo efficacy in antithrombotic models, the HCl salt of this compound was selected for clinical development as razaxaban (DPC 906, BMS-561389).

Nonbenzamidine tetrazole derivatives as factor Xa inhibitors

Factor Xa (fXa) is an important serine protease that holds the central position linking the intrinsic and extrinsic activation mechanisms in the blood coagulation cascade. Therefore, inhibition of fXa has potential therapeutic applications in the treatmen